Strides Pharma Science on Tuesday said its profit after tax increased 81% year-on-year to ₹114 crore for the first quarter ended June 30, 2025.
The company reported a profit after tax (PAT) of ₹63 crore for the April-June period of last year.
Revenue rose to ₹1,120 crore for the June quarter against ₹1,054 crore in the year-ago period, Strides Pharma Science said in a regulatory filing.
"Our focus on cost management and diligent execution has enabled us to deliver robust results," Strides Pharma Science MD & Group CEO Badree Komandur said.
The company will enhance its R&D efforts during the year to drive sustainable long-term growth, he added.
Shares of Strides Pharma were trading 4.71% higher at ₹965.95 apiece on the BSE.
